Since the terms 'hypertension' and 'microalbuminuria' were first defined, data from numerous studies have documented the continuous, rather than dichotomous, relation between blood pressure, albumin excretion, and cardiovascular disease. Lower blood pressures, down to at least 115/ 75 mmHg, and lower albumin excretions, below an estimated 2 mg/day, are associated with less cardiovascular risk. We hypothesize that the abundances of modern civilization superimposed on the Paleolithic genotype of humans, which has not substantially changed in the last 10 000 years, have considerably shifted the 'normal' values for blood pressure and various biochemical indices such as albuminuria still found in today's stone-aged cultures to the 'neo-normal' values observed today in the rest of the modern world. Defining a large portion of the population as 'normal' based upon these dichotomous 'neo-normal' standards is not supported by the data, and therefore seems unjustifiable. We propose that the medical community consider abandoning the terms 'hypertension' and 'microalbuminuria' in favor of 'blood pressure-associated' and 'albuminuria-associated' disease. The terms 'hypertension' and 'microalbuminuria' imply a threshold level for blood pressure and albuminuria below which disease risk is not seen. This terminology defines a large group of people as normal, and ignores the impact that even minor variations of blood pressure and albumin excretion may have on disease within the so-called normal range. In this article, we propose that the medical community consider abandoning these terms, discuss blood pressureand albuminuria-related disease risk, and review treatment targets for associated cardiovascular and renal protection.
HISTORY History of hypertension and the joint national committee
Following the first measurement of blood pressure in the femoral artery of a horse by Hales in 1733, and the recognition by Bright in 1827 that arteriosclerosis, shrunken and fibrotic kidneys, and cardiac hypertrophy were clinically linked, elevated blood pressure as a distinct entity was initially championed by T Clifford Allbutt in 1893, who was also the first to use the word 'hyperpiesia', or hypertension. Early pharmaceuticals were first used to treat malignant hypertension in the 1940s and 1950s, with significant improvements in outcomes. However, whether 'essential' hypertension (a term coined by Janeway in 1904) was a benign condition or one that would benefit from treatment was not answered until the VA Cooperative Studies published in 1967 and 1970.
Subsequently, the National High Blood Pressure Education Program, developed in 1972 by the National Heart, Lung, and Blood Institute, published the very first report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC 1) in 1977. 1 This report, whose bibliography included solely the VA study published seven years earlier, recommended intervention in patients with diastolic blood pressures (DBPs) greater than or equal to 90 mmHg; DBP4104 mmHg warranted drug therapy, whereas DBP 90-104 mmHg could initially be approached with risk factor reduction. Although the 1980 guidelines (JNC 2) defined mild, moderate, and severe hypertension along the same cutoffs of DBP, JNC 3 in 1984 included systolic blood pressure (SBP) ('normal' SBP being o140 mmHg) in the definition. 2, 3 Subsequent JNC guidelines in 1988, 1993, and 1997 adhered to the same definition of 'normal' blood pressure, with the recognition by JNC 5 of a 'high normal' category, and by JNC 6 of an 'optimal' category within the normal range. [4] [5] [6] The seventh report of the JNC recognized the associations between even small increments above 115/75 mmHg with cardiovascular outcomes, retreating somewhat from older definitions by reclassifying the 'high normal' group as 'prehypertension' instead. 7 Based upon the fourth National Health and Nutrition Examination Survey (1999-2000 NHANES), an estimated 58% -the majority of all adults in the United States -have abnormal blood pressure as defined by JNC 7 categories of prehypertension or hypertension. 8 Given the continuous association between blood pressure and risk as well as the absence of the J-curve, future progressive redefining of normality is all but assured, thus making the term 'hypertension' -a term which implies dichotomy -seem unjustifiable.
History of microalbuminuria
The term 'microalbuminuria' first appeared in the medical literature in 1981, used by Viberti and colleagues and Svendsen and colleagues to describe the presence of albuminuria below the detection limit of a standard dipstick, but at a level that was highly predictive of future overt proteinuria in diabetic patients. [9] [10] [11] Microalbuminuria became an official part of the medical lexicon in 1985, defined as an albumin excretion rate between 20 and 200 mg/min. Although the lower bound was chosen because 95% of 'normal' individuals had excretion rates below that limit, it was recognized that risk of progression to nephropathy was elevated among diabetics in the 'high normal' range.
12 Similar to the relationship between blood pressure and risk of cardiovascular events, mounting evidence indicates a continuous relationship between albumin excretion and risk. And like blood pressure, the concept of a threshold level to define normality is inconsistent with epidemiological data.
HYPOTHESIS 'Normal' from the vantage point of primitive vs modern anthropomorphism
The anthropologic record indicates that before the last 5000 to 10 000 years, Homo sapiens was considerably smaller in stature and body weight, 13 and presumably characterized by lower blood pressure, glomerular filtration rate, and cholesterol than are commonplace today. Stone-age tribes studied today confirm the anthropomorphic and biochemical patterns predicted for earlier humans. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] At the start of the Holocene 10 000 years ago, the earth's climate warmed, allowing people to establish villages and invent the basic tools of agriculture, herding, and metallurgy. Humans began to grow considerably in stature and body mass, and our 'paleonormal' physiologic values, perhaps lower than 90 mmHg for SBP, 100 mg/dl for total serum cholesterol, increased substantially to our current 'neo-normal' base of reference. 14, 16, 18, [20] [21] [22] [23] Neo-normal values can then be regarded as excessive to our paleophysiological and genetic heritage; hence, the benefit in risk reduction seen with therapies that return values closer to our original set points.
The general concept that our genetic heritage has been greatly outpaced by our modern environment, thus leading to increased weight, blood pressure, insulin resistance, and other medical problems, is forwarded by the 'thrifty-genotype' hypothesis. 25 'Thrifty' genes, which predispose us to low metabolic rates and salt conservation, evolved to preserve energy and blood pressure in Paleolithic humans faced with shortages in energy, salt, and with high physical demands. 26 Now faced with an abundance of food and sedentary lifestyles in modern humans, these thrifty genes have become associated with disease.
Isolated or 'primitive' cultures may arguably be the nearest representation of 'normal' human reference populations with respect to our genetic heritage. Many such populations have been identified, whose average blood pressures and cholesterol levels are very low, accompanied by low rates of cardiovascular disease. 27 Furthermore, blood pressure and serum cholesterol values do not increase with age as is commonly observed outside these isolated cultures. Regardless of the explanation for such phenomena, whether it be low salt consumption 28 or high intake of cocoa, 29 free-living people with average lifetime blood pressures of 90/60 mmHg are not hypotensive, but rather healthy and free from the cardiovascular morbidity and mortality so prevalent elsewhere. Thus, from the vantage point of primitive anthropomorphism, almost every adult in the United States and indeed most of the world has abnormally high blood pressure.
MISCONCEPTIONS The cholesterol example
The National Cholesterol Education Program does not define a cutoff value for 'hypercholesterolemia' . 30 Rather, the evidencebased guidelines for the prevention of cholesterol-associated disease include individualized treatment goals. For example, the treatment goal for a diabetic is different than the goal serum cholesterol level for someone with no cardiovascular risk factors. Furthermore, results from current and future trials will likely lead to adjusted guidelines and lower targets.
Epidemiologic evidence supports a continuous log-linear relationship between total serum cholesterol, low-density lipoprotein (LDL) cholesterol, and the risk of coronary heart disease in the general population. 31, 32 The continuous relationship persists down to an LDL as low as 40 mg/dl, with every 30 mg/dl higher LDL associated with a 30% increase in the relative risk of coronary heart disease. 31 Newer randomized trials similarly support the notion that lower is better. Data from the Heart Protection Study showed that all subgroups of high-risk individuals, including those whose starting pretrial LDL was o100 mg/dl, benefited from LDLlowering therapy. 33 These results were echoed by the PROVE IT study (Pravastatin or Atorvastatin Evaluation and Infection -Thrombolysis in Myocardial Infarction 22) in which a significantly lower risk of death or cardiovascular morbidity was obtained in high-risk patients with an achieved LDL of 62 mg/dl compared to 95 mg/dl. 34 Strikingly similar scenarios exist for blood pressure and albuminuria, as will be discussed. Taking a page from the Kidney International (2006) 69, 22-28 cholesterol playbook, the appropriate approach to blood pressure and urinary albumin excretion would be abandonment of 'hypertension' and 'microalbuminuria', and adoption of evidence-based treatment goals.
Blood pressure-associated disease
Blood pressure and blood pressure-associated disease should replace 'hypertension' in our lexicon. As pointed out by Rose, 35 and subsequently quoted by MacMahon et al., 36 high blood pressure can be operationally defined as the level at which further reductions do not lead to additional benefits. Treatment targets thus may differ among different comorbid groups, and targets are likely to change with future randomized trials of more intensive blood pressure lowering.
The misconception of the J-curve
In 1978, Anderson reported that re-examination of the Framingham Cohort unsmoothed blood pressure data revealed no additional benefits to DBPo90 mmHg vis-a-vis cardiovascular disease. 37 A year later, Stewart 38 proposed the concept of the J-curve, and this was followed by confirmation of the J-curve for DBP in participants of several blood pressure-lowering trials. [39] [40] [41] [42] Arguments against the J-curve hold that the increase in events at the lower end of the spectrum are, in fact, a result of reverse causality, in that coexistent comorbid disease such as congestive heart failure or vascular disease is responsible for both the higher risk of events and lower SBP or DBP.
Indeed, a 2004 examination of Framingham data implicates pre-existing cardiovascular disease as an explanation of higher risk at lower DBPs. The authors reported that the risk of cardiovascular events at DBPo90 mmHg was higher only among those with SBP4140 mmHg, suggesting that the J-curve for DBP may be explained by a widened pulse pressure and high SBP; when SBP was o140 mmHg, lower DBP decreased the risk of cardiovascular disease. 43 Moreover, many other trials have failed to show a J-curve, [44] [45] [46] whereas others demonstrating a J-curve could not fully account for baseline comorbidity such as the severity of pre-existing heart failure and vascular disease. 41, 42 Finally, in an analysis that combined individual data from almost one million participants with no baseline cardiovascular disease from 61 prospective studies, there was a linear association between both SBP and DBP and risk of cardiovascular mortality down to 115 mmHg SBP and 75 mmHg DBP. At blood pressures below these values, the risk of cardiovascular mortality was even lower. 47 The misconception of 'normotension'
The linear relationship between blood pressure and cardiovascular death just mentioned is reminiscent of the association between cholesterol and risk of coronary heart disease. Down to a blood pressure of 115/75 mmHg, every 10 mmHg lower usual systolic or 5 mmHg lower usual diastolic pressure is associated during long-term follow-up with a 40% reduction in risk of death from stroke and a 30% reduction in risk of death from ischemic heart disease. 47 These findings are consistent with other observational studies, 48 and once again argues that our current definition of normal be re-evaluated.
Results from randomized controlled trials have confirmed that a further reduction in blood pressure among 'normotensive' individuals indeed lowers the risk of cardiovascular events (Table 1) . These studies include populations where the 52 a requirement necessary to achieve adequate statistical power during the relatively short duration of a randomized trial.
Type II diabetics with baseline blood pressures o140/ 80 mmHg were randomized in the normotensive ABCD (Appropriate Blood pressure Control in Diabetes) trial to placebo or active treatment with either enalapril or nisoldipine. 45 During five years of follow-up, the incidence of strokes was 70% lower in the active treatment group (P ¼ 0.03) compared to the placebo group (mean BP 137/ 81 mmHg compared to 128/75 mmHg in the active treatment group). 45 Among a subset of these patients with peripheral vascular disease in addition to diabetes, the aggressive blood pressure treatment also reduced the risk of a combined cardiovascular end point of CV death, nonfatal stroke, and nonfatal myocardial infarction by approximately two-thirds. 50 Treatment of 'normotensive' diabetics with ramipril in the HOPE (Heart Outcomes Prevention Evaluation) study also resulted in a reduction of cardiovascular events. 49 The CAMELOT (Comparison of AMlodipine vs. Enalapril to Limit Outcomes of Thrombosis) study randomized 1991 individuals with angiographically confirmed coronary artery CAMELOT vs. Endapril to Limit Outcomes of Thrombosi (disease and a mean baseline blood pressure of 129/78 mmHg to either placebo or active treatment (10 mg of amlodipine or 20 mg of enalapril). 46 Active treatment resulted in a blood pressure separation from placebo of about 5/2.5 mmHg. During 2 years of follow-up, the occurrence of the cardiovascular end point was reduced by 30% with amlodipine therapy. Enalapril therapy lowered the risk by 20%, but this was not statistically significant. Among participants with known coronary artery disease in the EUROPA (EURopean trial On reduction of cardiac events with Perindopril with stable coronary Artery disease) study, active treatment led to a 20% lower cardiovascular event rate, along with an average 5/2 mmHg reduction in blood pressure compared to placebo; the results were consistent whether participants were 'hypertensive' or 'normotensive' at baseline. 51 The PROGRESS (Perindopril pROtection aGainst REcurrent Stroke) Study included 3189 'normotensive' participants with a prior stroke history and mean entry blood pressure at baseline of 136/79 mmHg. 52 They were randomized to either perindopril (resulting in a 5/3 mmHg fall in blood pressure), a combination of perindopril and indapamide (resulting in a 12/5 mmHg fall in blood pressure), or placebo. All vascular events were reduced by 24% with active therapy in this 'normotensive' group. However, combination therapy, concomitant with its greater effect on blood pressure, appeared more effective: combination therapy reduced the risk of recurrent stroke by 42% in these individuals.
Participants of the HOPE study had known cardiovascular disease or diabetes at baseline, and 53% had blood pressures o140/90 mmHg at entry. 49 Blood pressure separation with ramipril compared to placebo was 3/2 mmHg at the four study visits, but in fact may have been more substantial given the results of a substudy that measured ambulatory blood pressure. 53 Among the 'normotensive' group, the combined cardiovascular end point was reduced by 20% with active treatment.
Whether targeting a lower blood pressure goal of o130/ 80 mmHg compared to o140/90 mmHg reduces the risk of cardiovascular outcomes in another high-risk population, namely those with nondiabetic chronic kidney disease, remains undetermined. So far, three randomized trials have examined this question. [54] [55] [56] Although two did not show a significant benefit to lower targets within the normal range, the study with the longest follow-up and highest degree of statistical power demonstrated a significant reduction in both end-stage renal disease and all-cause mortality. 56 The MDRD (Modification of Diet in Renal Disease) Study achieved a blood pressure separation of approximately 8/3 mmHg (126/77 vs 134/80 mmHg) over 2 years; during an average of 6 years of follow-up, end-stage renal disease and all-cause death was reduced by 23% in the group with lower blood pressure. 56 Thus, the current evidence provides us with both the observation that the risk of cardiovascular events follows a linear relationship with blood pressure and with the clinical trial experimentation that achieving further blood pressures reductions within the so-called 'normal' range indeed reduces the risk of cardiovascular events.
Albuminuria-associated disease
'Microalbuminuria' is another term that should now be eliminated from our lexicon, as there are ample data to suggest that albuminuria in the 'normal' range carries significant risk of vascular events.
The misconception of normoalbuminuria
Any degree of non-negligible albuminuria bears a significant risk for cardiovascular events. Post hoc analyses of randomized trials in high-risk individuals as well as communitybased cohort studies all indicate that incremental increases in albuminuria within the 'normal' range carry higher risks of cardiovascular morbidity and mortality, elevations in blood pressure, and even noncardiovascular death (Table 2) . [57] [58] [59] [60] [61] [62] [63] [64] [65] Moreover, data from the Steno Diabetes Center in type I diabetics, as well as post hoc analyses of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) data in patients with type II diabetes, LIFE (Losartan Intervention For Endpoint) reduction in hypertension data in patients with 'hypertension', and African American Study of Kidney Disease and Hypertension data in African Americans with nondiabetic chronic kidney disease all suggest that the degree of albuminuria reduction in response to treatment is a primary determinant of both renal and cardiovascular outcomes.
Similar to cholesterol and blood pressure, there is a continuous relationship between the level of albumin excretion and the risk of cardiovascular events. The studies outlined in Table 2 , especially the data from HOPE, LIFE, and Framingham, clearly suggest that only negligible amounts of albuminuria should be considered normal. Specifically, levels above approximately 2 mg/g of creatinine (or an estimated excretion rate of 2 mg/day) are significantly associated with cardiovascular death, myocardial infraction, stroke, and elevation in blood pressure. 57, 58, 63 The HOPE and LIFE results further suggest that this association applies to both diabetics and nondiabetics alike. 57, 58 Although no randomized trials have specifically addressed the question of whether a reduction in albuminuria would result in a concomitant reduction in renal and cardiovascular events, multiple observations suggest this may be true. Parving and colleagues showed that the degree of albuminuria reduction during the first year of therapy was the best predictor of slowing progression of renal disease in type I diabetics. 55, 56 Among type II diabetics, the RENAAL investigators took advantage of a 6-month on-treatment re-evaluation of risk factors to determine if a decrease in albuminuria was associated with a favorable outcome. 68 After adjustment for multiple risk factors, a 30% or greater decrement in albumin excretion at 6 months was associated with a 35% reduction in the combined cardiovascular end point independent of the concomitant 6-month change in blood pressure, renal function, body size, or hemoglobin A1c. The PREVEND study did not normalize albumin excretions to creatinine.
In fact, among all risk-factor changes between baseline and 6 months, only persistent albuminuria was significantly predictive of cardiovascular events. Expressed as a continuous variable, every halving of albumin excretion was associated with an 18% lower risk of cardiovascular events. In a post hoc analysis of nondiabetics with kidney disease, the African American Study of Kidney Disease and Hypertension investigators examined whether 6-month on-treatment change in albuminuria predicted end-stage renal disease. 70 After adjustment for treatment arm and baseline albuminuria, a 20-50% reduction in albumin excretion at 6-months was associated with an approximate 50% lower risk of end-stage renal disease, and if albuminuria was lowered by more than half, the relative risk of end-stage renal disease was cut by almost 75%.
As with blood pressure, the available evidence argues that cardiovascular risk follows a continuous positive relationship with albumin excretion and that lowering albuminuria independently lowers the risk of renal and cardiovascular events.
WHAT IS NORMAL? A CENTRAL QUESTION WITH BROADER APPLICATION
The main thrust of this argument is that our current definitions of 'normal' for blood pressure and albuminuria are, in fact, abnormal, and that the terminology 'hypertension' and 'microalbuminuria' are misleading in suggesting dichotomy where associations are continuous. Observational data show that for both blood pressure and albuminuria, lower is clearly better in both high-and usual-risk individuals, whereas randomized trials illustrate benefit in treating high-risk individuals with 'normal' levels of blood pressure.
Because unguided pharmacotherapy is neither prudent nor feasible for clinicians and patients, and the risks of therapy must temper the absolute (rather than relative) benefits -which obviously differ by an individual's baseline risk of cardiovascular disease -the maintenance of guidelines employing categories of blood pressure and albuminuria is likely inevitable. Nevertheless, given that 'normal' is not normal, we urge that future randomized trials identify levels of blood pressure and albuminuria, below which further therapy is no longer beneficial.
In addition, we believe that our central question, 'what is normal', has broader applicability in clinical medicine, and should spark re-evaluation of 'normal' among a variety of parameters. For example, are risks associated with a fasting plasma glucose of 90 mg/dl the same as those associated with 125 mg/dl? Should the term 'impaired glucose tolerance' be re-evaluated? A body mass index of 24.9 imparts greater risk than a body mass index of 20 kg/m 2 ; should the arbitrary definition of 'normal' weight be changed? Many other examples probably exist. During the course of human history, our behavior and environment fell out of step from our genetic heritage, explaining the clinical benefits observed with closer proximity to paleo-rather than neonormality.
